Fintel reports that on July 14, 2025, HC Wainwright & Co. downgraded their outlook for Verona Pharma plc - Depositary Receipt ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Yahoo Finance Senior Reporter Anjalee Khemlani joins Morning Brief to discuss Merck's (MRK) pending $10 billion acquisition ...

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...

Merck (NYSE:MRK) is close to finalizing a deal worth around $10 billion to acquire Verona Pharma (NASDAQ:VRNA), a biotech ...

Global markets have been seesawing this week, as traders digest the latest trade tariff news. Overnight, Asia-Pacific markets ...